This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Invest in Chemed (CHE) Stock Right Now
by Zacks Equity Research
Chemed's (CHE) subsidiaries continue to register strong sales.
Chemed Grows on Robust VITAS & Roto-Rooter Despite Headwinds
by Zacks Equity Research
Chemed's (CHE) Roto-Rooter business is showing a marked improvement on solid segmental performances at the core plumbing and drain cleaning service plus a strong uptick in water restoration.
EHC vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
EHC vs. CHE: Which Stock Is the Better Value Option?
HCA (HCA) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
HCA (HCA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why Is Chemed (CHE) Down 2.4% Since Last Earnings Report?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bright Outlook for Outpatient and Home Healthcare Industry
by Zacks Equity Research
Here we discuss how outpatient and home healthcare have been creating opportunities for investors keen on parking their money in this space.
HCA (HCA) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
HCA (HCA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Chemed (CHE) Beats on Q3 Earnings, Raises 2018 Guidance
by Zacks Equity Research
The expansion in adjusted operating margin at Chemed (CHE) raises investor hopes on the stock.
Chemed (CHE) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 10.04% and 0.47%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Chemed (CHE) Ahead of Earnings?
by Zacks Equity Research
Chemed (CHE) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Chemed (CHE) Q3 Earnings Preview: What to Know Ahead of the Release
by Zacks Equity Research
Chemed (CHE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
EHC or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EHC vs. CHE: Which Stock Is the Better Value Option?
4 Stocks to Bet on the Burgeoning Home Healthcare Industry
by Sapna Bagaria
Growing senior population, increasing chronic illness, high cost of treatment at inpatient settings and preference by patients drives demand for home health care.
PRA Health Sciences (PRAH) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
PRA Health Sciences (PRAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
EHC or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EHC vs. CHE: Which Stock Is the Better Value Option?
Chemed (CHE) Down 0.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.
Why You Should Add Chemed (CHE) Stock to Your Portfolio Now
by Zacks Equity Research
Within Chemed's (CHE) VITAS business, management notes the recent admission trends to be consistently positive and this momentum is likely to continue.
EHC vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EHC vs. CHE: Which Stock Is the Better Value Option?
EHC vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EHC vs. CHE: Which Stock Is the Better Value Option?
STERIS (STE) Q1 Earnings & Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
STERIS (STE) continues to gain from strength in all business segments in Q1.
Haemonetics (HAE) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Haemonetics' (HAE) year-over-year growth is backed by the solid execution of its multi-year turnaround strategy.
Wright Medical (WMGI) Beats on Q2 Earnings, Raises '18 View
by Zacks Equity Research
Growth in the upper and lower extremity segments drives Wright Medical's (WMGI) Q2 results.
Bio-Rad (BIO) Tops Earnings and Revenue Estimates in Q2
by Zacks Equity Research
Bio-Rad's (BIO) solid growth in North America, China and Asia Pacific reflects strong international foothold in Q2.
CVS Health's (CVS) Q2 Earnings Beat Estimate, Margins Up
by Zacks Equity Research
CVS Health (CVS) reports strong Pharmacy Services revenues, benefiting from the upside in the specialty services. Year-over-year Retail/LTC comparisons are also encouraging.